- The sublingual administration of 5-MeO-DMT in adults with moderate anxiety and depression demonstrated good safety and tolerability, with no significant adverse events reported throughout the study.
- Pharmacokinetic assessments revealed that peak plasma concentrations were attained rapidly at approximately 20 minutes, without evidence of drug accumulation after repeated doses.
- Neurophysiological evaluations indicated dose-dependent modulation of brain activity without inducing full psychedelic effects, highlighting the potential of sub-psychedelic dosing strategies in therapeutic contexts.
Study Overview of Sublingual 5-MeO-DMT
This Phase I clinical trial investigated the safety, tolerability, and pharmacokinetics of sublingual 5-MeO-DMT administered at low doses to adults experiencing moderate to severe anxiety and depression. Participants received doses of 6 mg, 9 mg, or 12 mg weekly for four weeks. The results indicated that the compound was well-tolerated, with rapid absorption correlating with a peak plasma concentration occurring within about 20 minutes. Notably, participants maintained cognitive and behavioral function without experiencing full psychedelic effects.
The authors of this study explored the therapeutic potential of serotonergic psychedelics such as psilocybin and LSD, which are recognized for their therapeutic properties in treating mental health issues. Unlike many conventional psychoactive drugs, these psychedelics do not trigger compulsive use or withdrawal syndromes, which positions them as promising candidates for addressing various psychiatric conditions, including anxiety, depression, and PTSD.
Dosing Strategies and Pharmacological Aspects
The researchers noted an increasing interest in two main dosing strategies: macrodosing and microdosing. Macrodosing involves administering full psychedelic doses intended to elicit intense experiences, while microdosing entails taking sub-perceptual doses that aim to provide subtle improvements in mood and cognition. Microdosing may appeal to individuals reluctant to undergo full psychedelic experiences.
5-MeO-DMT is recognized as a potent short-acting psychedelic derived from plants and certain toad secretions. Its administration via oral means is rendered ineffective due to rapid degradation by monoamine oxidase enzymes, thus necessitating alternative methods such as sublingual application. This route enhances absorption, yielding rapid therapeutic effects suitable for outpatient treatment settings when compared to longer-lasting psychedelics like psilocybin.
Study Methods and Participants
The Phase I trial conducted by Bistue Millón and collaborators was randomized, double-blind, and placebo-controlled. The researchers aimed to assess the effects of sublingual 5-MeO-DMT on individuals with moderate anxiety and depression, excluding anyone currently undergoing psychiatric treatment or using psychoactive medications. Among those screened, 40 participants qualified, with 36 completing the study. The demographic primarily consisted of middle-aged adults, all naïve to psychedelic substances, minimizing the impact of expectation bias on results.
Pharmacokinetic and Subjective Measures
The pharmacokinetics of 5-MeO-DMT were examined in the study, indicating that plasma levels peaked around 20 minutes post-administration. The half-life was approximately 20-30 minutes, reinforcing the compound’s characterization as a short-duration psychedelic. Subjectively, ratings of altered experiences were consistently below thresholds for classes of psychedelics, indicating that while some effects were noted, they did not manifest as full-blown psychedelic experiences. These findings support the viability of microdosing as a therapy with low risk for adverse effects.
Results and Discussion
Throughout the four-week trial, no serious adverse events occurred, and cognitive assessments revealed no impairments related to memory or functioning. Mild transient effects like dizziness or nausea mostly occurred in the higher dose group and resolved on their own. The EEG recordings showed significant changes in brain activity corresponding to the dosing, affirming that the neurophysiological impact occurs even without full psychedelic experiences.
The results of this clinical trial provide compelling evidence for the safety and practicality of 5-MeO-DMT microdosing as a potential therapeutic strategy. The short onset and half-life cater to outpatient treatment scenarios, and the absence of cumulative effects could lead to flexible and safer practices for managing anxiety and depression. The authors advocate for further exploration of the efficacy of such low-dose interventions in clinical settings, focusing on longer-term psychological benefits and optimal dosage protocols. See also our coverage of Side Effects of Microdosing Lysergic Acid Diethylamide, and our explainers on major depressive disorder and side effects. Read the full paper summary on Blossom.
